Centuple Global Limited has announced a board meeting scheduled for March 18, 2026, to address important changes in its board composition. The company, formerly known as Checkpoint Trends Limited, will deliberate on the resignation and appointment of Non-Executive Independent Directors during this meeting.

Board Meeting Agenda

The board meeting will focus on two primary matters related to directorial changes:

Trading Window Restrictions

In compliance with regulatory requirements, the company has implemented trading window restrictions. The trading window for dealing in company securities will remain closed for all designated persons and their immediate relatives covered under the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders.

Company Information

Centuple Global Limited, previously operating as Checkpoint Trends Limited, maintains its registered office in Nashik, Maharashtra. The company operates under CIN L46307MH1991PLC326598 and trades on BSE with scrip code 531099. The announcement was signed by Managing Director Shubham Chaudhary on March 10, 2026.

The board meeting represents a routine corporate governance matter as the company manages its directorial composition in accordance with regulatory requirements and best practices.

Centuple Global Limited (formerly Checkpoint Trends Limited) has successfully completed the allotment of convertible warrants worth ₹75,04,99,981 through preferential allotment. The Board of Directors approved the allotment of 1,66,74,072 convertible warrants to 9 non-promoter investors on March 05, 2026.

Board Meeting Outcome

The Board meeting was held from 08:00 P.M. to 09:00 P.M. on March 05, 2026, with Managing Director and CFO Shubham Chaudhary (DIN: 09298013) signing the regulatory filings. The allotment was conducted under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Warrant Terms and Structure

The convertible warrants were issued at ₹45.01 per warrant, with each warrant carrying the right to subscribe to one equity share of face value ₹10. The warrants can be exercised in one or more tranches within 18 months from the allotment date. Investors have paid 25% of the warrant issue price upfront, totaling ₹18,76,25,005, with the remaining 75% payable upon conversion.

Investor Allocation Details

The warrants were allocated to 9 non-promoter investors, with the largest allocations going to institutional investors:

Regulatory Approvals

The company received in-principle approval from BSE Limited vide letter no. LOD/PREF/MV/FIP/1724/2025-26 dated February 18, 2026. The allotment was based on prior approvals from the Board meeting held on September 24, 2025, and shareholder approval in the extraordinary general meeting held on October 27, 2025. All payments were made in cash through the preferential allotment route.

Conversion Mechanism

Upon exercise of the warrants, fully paid-up equity shares of face value ₹10 each will be allotted to the warrant holders within 18 months from the allotment date. The amount paid against warrants will be adjusted against the issue price for the resultant equity shares, ensuring seamless conversion from warrants to equity participation.